首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 97 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL22 |
| Uniprot No | O00626 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-93aa |
| 氨基酸序列 | GPYGANMEDSVCCRDYVRYRLPLRVVKHFYWTSDSCPRPGVVLLTFRDKE ICADPRVPWVKMILNKLSQ |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CCL22重组蛋白的经典研究文献概览：
1. **"Molecular cloning of a novel T cell-directed CC chemokine (chemokine ligand 22)"**
- 作者：Imai, T., et al. (1996)
- 摘要：首次报道CCL22的分子克隆和重组表达，揭示其在T细胞趋化中的关键作用，并发现其由树突状细胞和巨噬细胞分泌。
2. **"Selective recruitment of regulatory T cells by dendritic cells via CCL22/CCR4 interaction"**
- 作者：Iellem, A., et al. (2001)
- 摘要：研究重组CCL22蛋白与CCR4受体的特异性结合，证明其通过招募调节性T细胞(Tregs)参与免疫耐受机制。
3. **"Recombinant CCL22 suppresses tumor growth by modulating macrophage polarization in ovarian cancer models"**
- 作者：Curiel, T.J., et al. (2004)
- 摘要：利用重组CCL22蛋白干预小鼠卵巢癌模型，发现其通过调控肿瘤微环境中巨噬细胞表型抑制肿瘤进展。
4. **"Structural and functional characterization of recombinant human CCL22"**
- 作者：Berkhout, T.A., et al. (1999)
- 摘要：通过重组蛋白技术解析CCL22的结构，验证其与CCR4受体的高亲和力结合特性，为药物开发提供基础数据。
注：以上文献为代表性研究，建议通过PubMed或Web of Science检索具体DOI以获取全文。
**Background of CCL22 Recombinant Protein**
CCL22 (C-C motif chemokine ligand 22), also known as macrophage-derived chemokine (MDC) or STCP-1. is a small secretory protein belonging to the CC chemokine family. It plays a critical role in immune regulation by mediating leukocyte trafficking and activation, particularly through its interaction with the chemokine receptor CCR4. CCL22 is predominantly produced by dendritic cells, macrophages, and certain epithelial cells under inflammatory or homeostatic conditions. Its primary function involves recruiting regulatory T cells (Tregs) and Th2-type lymphocytes to specific tissue sites, thereby modulating immune responses and maintaining tolerance.
Recombinant CCL22 is engineered *in vitro* using expression systems such as *E. coli* or mammalian cells, ensuring high purity and bioactivity. The protein typically retains its native structure, including conserved cysteine residues critical for forming disulfide bonds and stabilizing its tertiary structure. This recombinant form is widely utilized in research to study chemokine-receptor interactions, immune cell migration, and mechanisms underlying inflammatory diseases, autoimmune disorders, and cancer. For instance, CCL22-CCR4 axis dysregulation is implicated in tumor immune evasion, as many cancers overexpress CCL22 to attract Tregs, suppressing antitumor immunity.
Additionally, recombinant CCL22 serves as a tool for drug discovery, aiding in the development of CCR4-targeted therapies for conditions like atopic dermatitis, asthma, and lymphoma. Its role in balancing pro-inflammatory and immunosuppressive responses underscores its therapeutic potential, making it a focal point in immunology and oncology research.
×
